Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results